Drug Trial Radar · NCT07710196
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- Nacuity Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Foundation Fighting Blindness
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Conditions
- Retinitis Pigmentosa (RP)
- Usher Syndrome
Interventions
PlaceboDrug
Oral placebo tablet
NPI-001Drug
Oral n-acetyl cysteine amide tablet (250mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ellipsoid Zone AreaTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Retina Foundation of the Southwest
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.